| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | ETODOLAC | 3 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | LEVETIRACETAM | 3 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use topiramate tablets, USP safely and effectively. See full prescribing information for topiramate tablets, USPTopiramate Tablets, USP for oral use Initial U.S. Approval: 1996 | 5 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | ALPRAZOLAM | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | TOPIRAMATE | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | TOPIRAMATE | 6 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | NABUMETONE | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Inflamation Reduction Pack | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Triamterene and Hydrochlorothiazide Tablets, USP | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | LEVOFLOXACIN | 3 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Temazepam Capsules, USP CIV | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Gemfibrozil Tablets, USP 600 mg | 3 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Citalopram Tablets, USP Rx Only | 4 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | METOPROLOL TARTRATE TABLETS USP 0733 0734 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Triamterene and Hydrochlorothiazide Tablets, USP | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Sertraline Tablets, USP 25 mg, 50 mg and 100 mg Rx Only | 27 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use pantoprazole sodium delayed-release tablets safely and effectively. See full prescribing information for pantoprazole sodium delayed-release tablets. PANTOPRAZOLE sodium delayed-release tablets USP, for oral administration Initial U.S. approval: 2000 | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use levetiracetam tablets safely and effectively. See full prescribing information for levetiracetam tablets USP. Levetiracetam Tablets USP for Oral Use Initial U.S. Approval: 1999 | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use raloxifene hydrochloride tablets, USP safely and effectively. See full prescribing information for raloxifene hydrochloride tablets, USP. Raloxifene Hydrochloride Tablets, USP for Oral Use Initial U.S. Approval: 1997 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use duloxetine delayed-release capsules USP safely and effectively. See full prescribing information for duloxetine delayed-release capsules USP. DULOXETINE delayed-release capsules USP for oral use Initial U.S. Approval: 2004 | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Revised: August 2014 Mirtazapine Tablets, USP Rx only | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Desipramine Hydrochloride Tablets, USP | 1001 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use divalproex sodium extended-release tablets USP safely and effectively. See full prescribing information for divalproex sodium extended-release tablets USP. DIVALPROEX Sodium Extended-Release Tablets USP, for Oral Use Initial U.S. Approval: 2000 | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use TRICOR safely and effectively. See full prescribing information for TRICOR. TRICOR (fenofibrate) Tablet for oral use Initial U.S. Approval: 1993 | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use levetiracetam tablets safely and effectively. See full prescribing information for levetiracetam tablets. LEVETIRACETAM Tablets USP, for oral use Initial U.S. Approval: 1999 | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use metoprolol succinate extended-release tablets USP safely and effectively. See full prescribing information for metoprolol succinate extended release tablets USP. Metoprolol succinate extended-release tablets USP Initial U.S. Approval: 1992 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use quetiapine fumarate tablets safely and effectively. See full prescribing information for quetiapine fumarate tablets. QUETIAPINE fumarate tablets for oral use Initial U.S. Approval: 1997 | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Sertraline Hydrochloride Tablets 25 mg, 50 mg and 100 mg | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Topiramate Tablets | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Mirtazapine Tablets USP Revised: June 2012 Rx only | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use levetiracetam tablets safely and effectively. See full prescribing information for levetiracetam tablets. Levetiracetam Tablets USP, for oral use Initial U.S. Approval: 1999 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Fluvoxamine Maleate Tablets These highlights do not include all the information needed to use Fluvoxamine Maleate Tablets safely and effectively. See full prescribing information for Fluvoxamine Maleate Tablets. Fluvoxamine Maleate Tablets for oral administration Initial U.S. Approval: 1994 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | FENOFIBRATE TABLETS, 54 mg and 160 mg | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | METOPROLOL TARTRATE TABLETS USP | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Fluphenazine Hydrochloride Tablets, USP | 14 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Fluphenazine Hydrochloride Tablets, USP | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use levetiracetam tablets safely and effectively. See full prescribing information for levetiracetam tablets USP. Levetiracetam Tablets USP for Oral Use Initial U.S. Approval: 1999 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | CYCLOBENZAPRINE HYDROCHLORIDE TABLETS USP | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Levetiracetam Tablets Rx Only Revised: March, 2011 | 3 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Temazepam Capsules, USP CIV | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | METOPROLOL TARTRATE TABLETS USP 0733 0734 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Amoxicillin and Clavulanate Potassium Tablets USP, Amoxicillin and Clavulanate Potassium for Oral Suspension USP, and Amoxicillin and Clavulanate Potassium Tablets USP (Chewable) safely and effectively. See full prescribing information for Amoxicillin and Clavulanate Potassium Tablets USP, Amoxicillin and Clavulanate Potassium for Oral Suspension USP, and Amoxicillin and Clavulanate Potassium Tablets USP | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use fluoxetine capsules USP safely and effectively. See full prescribing information for fluoxetine capsules USP. FLUOXETINE capsules USP for oral use Initial U.S. Approval: 1987x | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | PAROXETINE TABLETS USP, 10 mg, 20 mg, 30 mg and 40 mg 7114 7115 7116 7121 Rx only | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Sertraline Hydrochloride Tablets 25 mg, 50 mg and 100 mg | 4 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Sertraline Hydrochloride Tablets 25 mg, 50 mg and 100 mg | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use levofloxacin tablets safely and effectively. See full prescribing information for levofloxacin tablets. LEVOFLOXACIN tablets for oral use Initial U.S. Approval: 1996 To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. | 1000 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use carvedilol tablets USP safely and effectively. See full prescribing information for carvedilol tablets USP. CARVEDILOL tablets USP for oral use Initial U.S. Approval: 1995 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Triamterene and Hydrochlorothiazide Tablets, USP | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use metoprolol succinate extended-release tablets USP safely and effectively. See full prescribing information for metoprolol succinate extended release tablets USP. Metoprolol succinate extended-release tablets USP Initial U.S. Approval: 1992 | 3 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Mirtazapine Tablets USP Revised: June 2012 Rx only | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | AMOXICILLIN AND CLAVULANATE POTASSIUM TABLETS USP, 500 mg/125 mg and 875 mg/125 mg 2274 2275 Rx only | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use AVANDAMET safely and effectively. See full prescribing information for AVANDAMET. AVANDAMET (rosiglitazone maleate and metformin hydrochloride) Tablets Initial U.S. Approval: 2002 | 6 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | 4aad770b-a342-45c5-8199-21a124060314 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Mirtazapine Tablets USP Revised: June 2008 Rx only | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use lamivudine and zidovudine tablets USP safely and effectively. See full prescribing information for lamivudine and zidovudine tablets USP. LAMIVUDINE and ZIDOVUDINE tablets, USP 150 mg/300 mg for oral use Initial U.S. Approval: 1997 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Drug Facts | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use levofloxacin tablets safely and effectively. See full prescribing information for levofloxacin tablets. LEVOFLOXACIN tablets for oral use Initial U.S. Approval: 1996 To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Drug Facts | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use lamivudine and zidovudine tablets USP safely and effectively. See full prescribing information for lamivudine and zidovudine tablets USP. LAMIVUDINE and ZIDOVUDINE tablets, USP 150 mg/300 mg for oral use Initial U.S. Approval: 1997 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | AMOXICILLIN AND CLAVULANATE POTASSIUM TABLETS USP, 500 mg/125 mg and 875 mg/125 mg 2274 2275 Rx only | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Triamterene and Hydrochlorothiazide Tablets, USP | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Clarithromycin Tablets, USP | 3 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Levetiracetam | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Mirtazapine Tablets USP Revised: June 2008 Rx only | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Citalopram Tablets, USP | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | AMOXICILLIN AND CLAVULANATE POTASSIUM TABLETS USP, 500 mg/125 mg and 875 mg/125 mg 2274 2275 Rx only | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Temazepam Capsules, USP CIV | 2 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Sertraline Hydrochloride Tablets 25 mg, 50 mg and 100 mg | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use carvedilol tablets USP safely and effectively. See full prescribing information for carvedilol tablets USP. CARVEDILOL tablets USP for oral use Initial U.S. Approval: 1995 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use metoprolol succinate extended-release tablets USP safely and effectively. See full prescribing information for metoprolol succinate extended release tablets USP. Metoprolol succinate extended-release tablets USP Initial U.S. Approval: 1992 | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use levofloxacin tablets safely and effectively. See full prescribing information for levofloxacin tablets. LEVOFLOXACIN tablets for oral use Initial U.S. Approval: 1996 To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use levofloxacin tablets safely and effectively. See full prescribing information for levofloxacin tablets. LEVOFLOXACIN tablets for oral use Initial U.S. Approval: 1996 To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. | 3 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Sertraline Hydrochloride Tablets 25 mg, 50 mg and 100 mg | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use metoprolol succinate extended-release tablets USP safely and effectively. See full prescribing information for metoprolol succinate extended release tablets USP. Metoprolol succinate extended-release tablets USP for Oral Use Initial U.S. Approval: 1992 | 3 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Lorazepam Tablets, USP | 6 |
| HYPROMELLOSE 2910 (3 MPA.S) | ACTIVE INGREDIENT | Nature's Tears Drug Facts | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Desipramine Hydrochloride Tablets, USP | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Tramadol Hydrochloride and Acetaminophen Tablets 37.5 mg/325 mg | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS 7.5 mg/200 mg | 1 |
| HYPROMELLOSE 2910 (3 CPS) | INACTIVE INGREDIENT | Tramadol Hydrochloride and Acetaminophen Tablets 37.5 mg/325 mg | 2 |
| HYPROMELLOSE 2910 (3 CPS) | INACTIVE INGREDIENT | Desipramine Hydrochloride Tablets, USP | 1 |
| HYPROMELLOSE 2910 (3 CPS) | INACTIVE INGREDIENT | Ranitidine Tablets, USP and Ranitidine Capsules | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | FENOFIBRATE TABLETS, 54 mg and 160 mg | 2 |
| HYPROMELLOSE 2910 (3 CPS) | INACTIVE INGREDIENT | 71d80d65-592d-4eec-84ba-d6f97c135161 | 1 |
| hypromellose 2910 (3 cps) | INACTIVE INGREDIENT | These highlights do not include all the information needed to use Ranexa safely and effectively. See full prescribing information for Ranexa. Ranexa (ranolazine) extended-release tablets Initial U.S. Approval: 2006 | 2 |
| HYPROMELLOSE 2910 (3 CPS) | INACTIVE INGREDIENT | Ranitidine Tablets, USP and Ranitidine Capsules | 1 |
| HYPROMELLOSE 2910 (3 CPS) | INACTIVE INGREDIENT | ef14122b-7fff-45fa-b13b-0ea9e48bd57d | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | Methazolamide Tablets, USP | 1 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | CITALOPRAM TABLET [LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC] | 3973 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | HYDROCODONE BITARTRATE AND IBUPROFEN TABLET, FILM COATED [LAKE ERIE MEDICAL DBA QUALITY CARE PRODUCTS LLC] | 3325 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | TRICOR (FENOFIBRATE) TABLET [ABBVIE INC.] | 1426 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | LEVETIRACETAM TABLET, FILM COATED [BRYANT RANCH PREPACK] | 1001 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | NALTREXONE HYDROCHLORIDE TABLET, FILM COATED [BRYANT RANCH PREPACK] | 1001 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | TRIAMTERENE HYDROCHLOROTHIAZIDE (TRIAMTERENE AND HYDROCHLOROTHIAZIDE) TABLET [BRYANT RANCH PREPACK] | 1001 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | LEVOFLOXACIN TABLET, FILM COATED [BRYANT RANCH PREPACK] | 1000 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | PANTOPRAZOLE SODIUM TABLET, DELAYED RELEASE [BRYANT RANCH PREPACK] | 1000 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | REQUIP (ROPINIROLE) TABLET, FILM COATED [BRYANT RANCH PREPACK] | 1000 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | PROTONIX DELAYED-RELEASE (PANTOPRAZOLE SODIUM) TABLET, DELAYED RELEASE PROTONIX DELAYED-RELEASE (PANTOPRAZOLE SODIUM) GRANULE, DELAYED RELEASE [WYETH PHARMACEUTICALS INC., A SUBSIDIARY OF PFIZER INC.] | 26 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | GLYBURIDE AND METFORMIN HYDROCHLORIDE TABLET, FILM COATED [TEVA PHARMACEUTICALS USA INC] | 19 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | DESIPRAMINE HYDROCHLORIDE TABLET, FILM COATED [SANDOZ INC] | 18 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | MIRTAZAPINE TABLET, FILM COATED [ACTAVIS PHARMA, INC.] | 18 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | RANITIDINE HYDROCHLORIDE CAPSULE RANITIDINE HYDROCHLORIDE TABLET, FILM COATED [SANDOZ INC] | 18 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | AMOXICILLIN AND CLAVULANATE POTASSIUM TABLET, FILM COATED AMOXICILLIN AND CLAVULANATE POTASSIUM POWDER, FOR SUSPENSION AMOXICILLIN AND CLAVULANATE POTASSIUM TABLET, CHEWABLE [TEVA PHARMACEUTICALS USA INC] | 16 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | ARICEPT (DONEPEZIL HYDROCHLORIDE) TABLET, FILM COATED ARICEPT ODT (DONEPEZIL HYDROCHLORIDE) TABLET, ORALLY DISINTEGRATING [EISAI INC.] | 16 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | TROSPIUM CHLORIDE CAPSULE, EXTENDED RELEASE [ACTAVIS PHARMA, INC.] | 16 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | BENAZEPRIL HYDROCHLORIDE TABLET, FILM COATED [AUROBINDO PHARMA LIMITED] | 15 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | CLARITHROMYCIN TABLET [PD-RX PHARMACEUTICALS, INC.] | 15 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | CLARITHROMYCIN TABLET [SANDOZ INC] | 15 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN KIT [SANDOZ INC] | 15 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | LEVETIRACETAM TABLET, FILM COATED [AUROBINDO PHARMA LIMITED] | 15 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | TOPIRAMATE TABLET, FILM COATED TOPIRAMATE (TOPIRAMATE ) TABLET, FILM COATED [AUROBINDO PHARMA LIMITED] | 15 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN TABLET, FILM COATED [MICRO LABS LIMITED] | 15 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | CIPROFLOXACIN TABLET, FILM COATED [IVAX PHARMACEUTICALS, INC.] | 14 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | PAROXETINE (PAROXETINE HYDROCHLORIDE) TABLET, FILM COATED [AUROBINDO PHARMA LIMITED] | 14 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | CEPHALEXIN CAPSULE CEPHALEXIN POWDER, FOR SUSPENSION CEPHALEXIN TABLET [TEVA PHARMACEUTICALS USA INC] | 13 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | CIPROFLOXACIN TABLET, FILM COATED, EXTENDED RELEASE [WATSON PHARMA, INC.] | 13 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE TABLET, FILM COATED [AUROBINDO PHARMA LIMITED] | 13 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | MONTELUKAST SODIUM GRANULE [DR.REDDY'S LABORATORIES LIMITED] | 12 |
| HYPROMELLOSE 2910 (3 MPA.S) | INACTIVE INGREDIENT | PERPHENAZINE TABLET, FILM COATED [SANDOZ INC] | 12 |
mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1300449
ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C82311
precision.fda.gov/uniisearch/srs/unii/0VUT3PMY82